It is after a gap of some time that Orchid Pharma, once a hot fav in pharma sector on Dalal Street is back in some news today.

The company announced that it has launched a new drug which will counteract Urinary Tract Infection (UTI). The drug - Cefepime-Enmetazobactam, has been approved for the treatment of complicated UTI, Hospital-Acquired Pneumonia (HAP) and Ventilator-Associated Pneumonia (VAP). Not just UTI, this drug can also fight the Superbug or Antibiotic Resistance.

The company said that with increasing resistance to the current drugs most commonly used for treatment,  doctors were forced to start using Carbapenems – a reserve drug meant to be used when most other drugs don't work. Now, Orchid's Cefepime-Enmetazobactam will allow doctors to spare Carbapenems, prolonging their effective life by restricting their use.

The stock is in the green today; from its close of Rs.1139.85, the stock opened at Rs.1161.75 and rose to an intraday high at Rs.1188.10. Its 52-week high is at Rs.1358.80.